OriGene Technologies’ vision is to prepare comprehensive, genome wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Our flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collection and over 25,000 TrueORF cDNA clones. From our TrueORF cDNA clones, we have developed the largest offering of full length human proteins. In addition, OriGene offers unique gene expression products such as TissueScan cancer qPCR arrays for biomarker discovery and validation. In October 2009, OriGene acquired Marligen Biosciences, Inc., and now offers nucleic acid purification products and Luminex multiplex detection assays for protein and nucleic acid detection.

www.marligen.com/multiplex-assays.html

OriGene’s goal is to leverage its genome wide protein and antibody portfolio to build the most comprehensive multiplex protein detection assays on xMAP platform. Right now OriGene offers a Luminex immunoassay development service. In addition, the company has built a leading product portfolio for nucleic acid detection, including genome wide microRNA assays, multiplex assays for the detection and quantitation of activated transcription factors, and products and services for SNP genotyping.

OriGene assay development team has many years of experience in developing research and diagnostic assays on xMAP platform. Our genome wide protein and antibody portfolio enables OriGene to be the best choice in Luminex assay development and services.